Evidence map›Paper›PMID 30685685›Full record

Trial reportEuropean journal of cancer (Oxford, England : 1990)2019

Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort.

Sigbjørn Smeland, Stefan S Bielack, Jeremy Whelan, Mark Bernstein, Pancras Hogendoorn, Mark D Krailo, Richard Gorlick, Katherine A Janeway, Fiona C Ingleby, Jakob Anninga and 42 more

Registry-linked trialAbstract readClinical Trial, Phase IIIMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in European journal of cancer (Oxford, England : 1990), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04890067 (Multicenter Observational Study on the Treatment of Patients With Localized Osteosarcoma), which is not on this map. Cited by 399 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
399citing papers in PubMed, 6 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04890067 recruitingnot on this mapstarted 2021, after this paper: background citation

Multicenter Observational Study on the Treatment of Patients With Localized Osteosarcoma

TypeobservationalSponsorItalian Sarcoma GroupRan2021 to 2026Enrolled120ConditionsLocalized OsteosarcomaArmsTreatment of Osteosarcoma according the AIEOP/ISG OS 2021 recommendations (includes drugs, surgery, radiotherapy or any other received treatments)
3 · Its place in the literature

Who cites it

399 citing papers in PubMed, 6 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Trial
  9. Trial
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Review
  19. Article
  20. Article

339 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

52 authors.

Sigbjørn SmelandSSG Oslo University Hospital and Scandinavian Sarcoma Group and Institute for Clinical Medicine, University of Oslo, Norway. Electronic address: ssm@ous-hf.no.
Stefan S BielackCOSS Klinikum Stuttgart - Olgahospital Stuttgart, Germany.
Jeremy WhelanEOI University College Hospital, London, UK.
Mark BernsteinCOG IWK Health Center, Dalhousie University, Halifax, NS, Canada.
Pancras HogendoornTMG Path Leiden University Medical Centre, Leiden, Netherlands.
Mark D KrailoCOG Children's Oncology Group, Arcadia, CA, USA.
Richard GorlickCOG the University of Texas M D Anderson Cancer Center, Houston, TX, USA.
Katherine A JanewayCOG Dana-Farber Cancer Institute, Boston, MA, USA.
Fiona C InglebyCDC MRC Clinical Trials Unit at UCL, London, UK.
Jakob AnningaEOI, Netherlands.
Imre AntalCOSS Semmelweis Egyetem Budapest, Budapest, Hungary.
Carola ArndtCOG Mayo Clinic, Rochester, MN, USA.
Ken L B BrownCOG University of British Columbia, Vancouver, BC, Canada.
Trude Butterfass-BahloulEISD Centre for Clinical Trials, University Hospital Muenster, Muenster, Germany.
Gabriele CalaminusQLCC Pädiatrische Hämatologie und Onkologie, Universitätsklinikum Bonn, Bonn, Germany.
Michael CapraEOI Our Lady's Children's Hospital, Dublin, Ireland.
Catharina DhoogeEOI University Hospital Ghent, Gent, Belgium.
Mikael ErikssonSSG Lund University, Lund, Sweden.
Adrienne M FlanaganEOI Royal National Orthopaedic Hospital, Stanmore; Cancer Institute, University College London, London, UK.
Godehard FriedelCOSS Klinik Schillerhöhe - Thoraxchirurgie Gerlingen, Germany.
Mark C GebhardtCOG Dana-Farber Cancer Institute, Boston, MA, USA.
Hans GelderblomEOI Leiden University Medical Center, Leiden, the Netherlands.
Robert GoldsbyCOG UCSF Medical Center-Mission Bay, Pediatric Oncology, San Francisco, CA, USA.
Holcombe E GrierCOG Dana-Farber Cancer Institute, Boston, MA, USA.
Robert GrimerEOI Royal Orthopaedic Hospital, Birmingham, UK.
Douglas S HawkinsCOG University of Washington, Seattle, WA, USA.
Stefanie Hecker-NoltingCOSS Klinikum Stuttgart - Olgahospital Stuttgart, Germany.
Kirsten Sundby HallSSG Oslo University Hospital, Oslo, Norway.
Michael S IsakoffCOG Connecticut Children's Medical Center, Hartford, CT, USA.
Gordana JovicCDC MRC Clinical Trials Unit at UCL, London, UK.
Thomas KühneCOSS Universitätsspital Basel, Basel, Switzerland.
Leo KagerCOSS St. Anna Kinderspital /CCRI, Wien, Austria.
Thekla von KalleCOSS Klinikum Stuttgart - Olgahospital Stuttgart, Germany.
Edita KabickovaCOSS University Hospital MOTOL, Praha, Czech Republic.
Susanna LangCOSS Medizinische Universität Wien, Vienna, Austria.
Ching C LauCOG Baylor College of Medicine, Houston, TX, USA.
Patrick J LeaveyCOG Southwestern and Children's Medical Center, Dallas, TX, USA.
Stephen L LessnickCOG Nationwide Children's Hospital and the Ohio State University, Columbus, OH, USA.
Leo MascarenhasCOG Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
Regine Mayer-SteinackerCOSS Universitätsklinikum Ulm, Ulm, Germany.
Paul A MeyersCOG Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Raj NagarajanCOG Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.
R Lor RandallCOG Primary Childrens Hospital, The University of Utah, Salt Lake City, UT, USA.
Peter ReichardtCOSS Helios Kliniken Berlin-Buch, Berlin, Germany.
Marleen RenardEOI University Hospital Leuven, Leuven, Belgium.
Catherine RechnitzerSSG Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
Cindy L SchwartzCOG the University of Texas M D Anderson Cancer Center, Houston, TX, USA.
Sandra StraussEOI University College Hospital, London, UK.
Lisa TeotCOG Boston Children's Hospital, Boston, MA, USA.
Beate TimmermannCOSS Universitätsklinikum Essen, Essen, Germany.
Matthew R SydesCDC MRC Clinical Trials Unit at UCL, London, UK. Electronic address: mrcctu.euramos@ucl.ac.uk.
Neyssa MarinaCOG Five Prime Therapeutics, Inc South San Francisco, CA, USA.

Funding

NCTN BIQSFP ANBL1531 (NRT)U10CA180886 · NCI · PUBLIC HEALTH INSTITUTE · PI Douglas S. Hawkins · 2014 to 2026
$390.6M
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Elisa de Stanchina · 1985 to 2026
$347.4M
Project 5P01CA106450 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI O'REILLY, RICHARD JOHN · 2005 to 2009
$12.4M
Medical Research Council MC_UU_12023/28NCI NIH HHS P01 CA106450NCI NIH HHS P30 CA008748NCI NIH HHS U10 CA180886
6 · The paper itself

Abstract

backgroundHigh-grade osteosarcoma is a primary malignant bone tumour mainly affecting children and young adults. The European and American Osteosarcoma Study (EURAMOS)-1 is a collaboration of four study groups aiming to improve outcomes of this rare disease by facilitating randomised controlled trials.

methodsPatients eligible for EURAMOS-1 were aged ≤40 years with M0 or M1 skeletal high-grade osteosarcoma in which case complete surgical resection at all sites was deemed to be possible. A three-drug combination with methotrexate, doxorubicin and cisplatin was defined as standard chemotherapy, and between April 2005 and June 2011, 2260 patients were registered. We report survival outcomes and prognostic factors in the full cohort of registered patients.

resultsFor all registered patients at a median follow-up of 54 months (interquartile range: 38-73) from biopsy, 3-year and 5-year event-free survival were 59% (95% confidence interval [CI]: 57-61%) and 54% (95% CI: 52-56%), respectively. Multivariate analyses showed that the most adverse factors at diagnosis were pulmonary metastases (hazard ratio [HR] = 2.34, 95% CI: 1.95-2.81), non-pulmonary metastases (HR = 1.94, 95% CI: 1.38-2.73) or an axial skeleton tumour site (HR = 1.53, 95% CI: 1.10-2.13). The histological subtypes telangiectatic (HR = 0.52, 95% CI: 0.33-0.80) and unspecified conventional (HR = 0.67, 95% CI: 0.52-0.88) were associated with a favourable prognosis compared with chondroblastic subtype. The 3-year and 5-year overall survival from biopsy were 79% (95% CI: 77-81%) and 71% (95% CI: 68-73%), respectively. For patients with localised disease at presentation and in complete remission after surgery, having a poor histological response was associated with worse outcome after surgery (HR = 2.13, 95% CI: 1.76-2.58). In radically operated patients, there was no good evidence that axial tumour site was associated with worse outcome.

conclusionsIn conclusion, data from >2000 patients registered to EURAMOS-1 demonstrated survival rates in concordance with institution- or group-level osteosarcoma trials. Further efforts are required to drive improvements for patients who can be identified to be at higher risk of adverse outcome. This trial reaffirms known prognostic factors, and owing to the large numbers of patients registered, it sheds light on some additional factors to consider.

Indexed as

AdolescentAdultAntineoplastic Combined Chemotherapy ProtocolsBone NeoplasmsChildCisplatinCohort StudiesDoxorubicinFemaleFollow-Up StudiesHumansMaleMethotrexateNeoplasm MetastasisOsteosarcomaPrognosisCisplatinDoxorubicinMethotrexateChemotherapyCohortOsteosarcomaOutcomesSurgery

Identifiers

PMID30685685
PMCPMC6506906

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.